z-logo
open-access-imgOpen Access
Sorafenib for Advanced and Refractory Desmoid Tumors
Author(s) -
Mrinal M. Gounder,
Michelle R. Mahoney,
Brian A. Van Tine,
Vinod Ravi,
Steven Attia,
Hari A. Deshpande,
Abha A. Gupta,
Mohammed Milhem,
Robert M. Conry,
Sujana Movva,
Michael J. Pishvaian,
Richard F. Riedel,
Tarek Sabagh,
William D. Tap,
Natally Horvat,
Ethan Basch,
Lawrence H. Schwartz,
Robert G. Maki,
Narasimhan P. Agaram,
Robert A. Lefkowitz,
Yousef Mazaheri,
Rikiya Yamashita,
James R. Wright,
Amylou C. Dueck,
Gary K. Schwartz
Publication year - 2018
Publication title -
new england journal of medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 19.889
H-Index - 1030
eISSN - 1533-4406
pISSN - 0028-4793
DOI - 10.1056/nejmoa1805052
Subject(s) - sorafenib , refractory (planetary science) , medicine , oncology , materials science , hepatocellular carcinoma , metallurgy
Desmoid tumors (also referred to as aggressive fibromatosis) are connective tissue neoplasms that can arise in any anatomical location and infiltrate the mesentery, neurovascular structures, and visceral organs. There is no standard of care.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom